TITLE

FDA Updates

AUTHOR(S)
Elliott, William T.
PUB. DATE
December 2008
SOURCE
Travel Medicine Advisor;Dec2008 Supplement, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the updates made by the U.S. Food and Drug Administration (FDA). A beta-blocker for the cure of benign prostatic hyperplasia has been approved by the former. According to the author, Silodosin is an a-1 receptor blocker closely related to prostate, bladder and urethra. The FDA also investigates a report for the Institute of Safe Medication Practices about Varenicline, the smoking cessation drug of Pfizer.
ACCESSION #
35638046

 

Related Articles

  • Combination therapy approved for BPH.  // Drug Topics;5/3/2004, Vol. 148 Issue 9, p6 

    This article reports on the U.S. Food and Drug Administration approval of finasteride for use in combination with doxazosin to reduce the risk of symptoms of benign prostatic hyperplasia from progressing over time.

  • FDA Updates. Elliott, William T. // Infectious Disease Alert;Dec2008 Pharmacology Watch, p2 

    The article offers information on drug approval by the U.S. Food and Drug Administration (FDA) as of December 2, 2008. Silidosin is an α-1 receptor blocker for treatment of benign prostatic hyperplasia. A report for the Institute of Safe Medication Practices on varencline, a smoking cessation...

  • FDA Updates.  // Critical Care Alert;Dec2008 Pharmacology Watch, p2 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved silodosin, a selective alpha-blocker for the treatment of benign prostatic hyperplasia.

  • GlaxoSmithKline: combo drug set to become blockbuster.  // PharmaWatch: Cancer;Aug2010, Vol. 9 Issue 8, p8 

    In this article, the author discusses the U.S. Food and Drug Administration (FDA) approval of GlaxoSmithKline's combination drug Jalyn for the treatment of benign prostatic hyperplasia (BPH). The author emphasizes that Jalyn will face various challenges such as ensuring the reimbursement of the...

  • News Briefs.  // American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1499 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved a new formulation of docetaxel and a needleless intravenous (i.v.) connector with chlorhexidine and silver and zero-fluid displacement.

  • Slew of approvables.  // Drug Topics;11/17/2003, Vol. 147 Issue 22, p27 

    Lists several approval drugs by the U.S. Food and Drug Administration. Ranexa to treat chronic angina; Insulin determir, a long-acting form of the diabetes drug; Fortament, an extended-release product to lower blood glucose.

  • FDA actions in brief.  // Formulary;Feb2010, Vol. 45 Issue 2, p42 

    The article discusses news briefs about drugs approved by the U.S. Food and Drug Administration (FDA). The drugs include dalfampridine extended release tablets, tocilzumab and morphine sulfate oral solution.

  • Pipeline preview.  // Formulary;Apr2010, Vol. 45 Issue 4, p113 

    The article offers U.S. Food & Drug Administration (FDA) drug approval news briefs. Miglustat has been approved for the treatment of Niemann-Pick type C disease, pirfenidone has been recommended for approval to improve lung function and pixantrone has been recommended not to be approved.

  • FDA actions in brief.  // Formulary;Apr2010, Vol. 45 Issue 4, p114 

    The article presents a list of drugs approved by the U.S. Food & Drug Administration (FDA) including doxepin for the treatment of insomnia, adapalene lotion for the treatment of acne and somatropin injection for the treatment of growth hormone disorders.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics